Larimar Therapeutics, Inc. (LRMR) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 8 Buy.
The consensus price target is $12.00, representing an upside of 146.4% from the current price $4.87.
Analysts estimate Earnings Per Share (EPS) of $-1.21 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.32 vs est $-1.21 (missed -9.2%). 2025: actual $-2.27 vs est $-1.95 (missed -16.3%). Analyst accuracy: 89%.
LRMR Stock — 12-Month Price Forecast
$12.00
▲ +146.41% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Larimar Therapeutics, Inc., the price target is $12.00.
The average price target represents a +146.41% change from the last price of $4.87.
LRMR Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Larimar Therapeutics, Inc. in the past 3 months
EPS Estimates — LRMR
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.32
vs Est –$1.21
▼ 8.4% off
2025
Actual –$2.27
vs Est –$1.95
▼ 14.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — LRMR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
